期刊文献+

神经生长因子鼻腔给药对MPTP致帕金森病模型小鼠的神经保护作用 被引量:5

Neuroprotective effect of intranasal administration of nerve growth factor in the mouse MPTP model of Parkinson's disease
原文传递
导出
摘要 目的:观察神经生长因子(nerve growth factors,NGF)鼻腔给药对于1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP)所致的帕金森病模型小鼠的神经保护作用。方法:通过自主活动实验和滚筒实验研究动物的行为表现,通过高效液相电化学检测方法观察脑纹状体多巴胺的变化,检测纹状体内超氧化物歧化酶(SOD)以及谷胱甘肽-S转移酶(GSH-S)的活性。通过脑黑质酪氨酸羟化酶(tyroxine hydroxylase,TH)免疫组化染色观察多巴胺能神经元的损伤程度。结果:在注射MPTP前鼻腔给予NGF,能够改善其行为学,增加纹状体内多巴胺及其代谢产物的含量,增加纹状体内SOD以及GSH-S的活性,差异均有统计学意义(P<0.05或0.01)。免疫组织化学结果表明,鼻腔给予NGF后,TH阳性细胞数有所增加。结论:NGF鼻腔给药对于MPTP模型具有神经保护作用。 Objective : To investigate the neuroprotective effect of intranasal administration of nerve growth factor ( NGF ) against 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine ( MPTP )-induced dopaminergic toxicity. Methods: The behaviors of C57 mice were assessed using the spontaneous movement and rotarod tests. DA levels in the striatum were measured using HPLC-EC. We also determined the activities of SOD and GSH-S in the stria- turn. Dopaminergic neurons in the substantia nigra were observed by immunohistochemical staining with anti-tyrox- ine hydroxylase(TH) antibody. Results: When intranasally administered before MPTP, NGF reduced behavioral deficits, increased the levels of dopamine and dopamine metabolites in the striatum, and increased striatal SOD and GSH-S activity as compared to mice treated with MPTP alone. Immunohistochemical study with anti-tyrosine hydroxylase antibody showed that intranasal administration of NGF had a protective effect against MPTP-induced neuronal damage in the substantia nigra of mice. Conclusion: When intranasally administered before MPTP, NGF may be able to protect C57 mice against MPTP-induced neuronal damage.
出处 《中国新药杂志》 CAS CSCD 北大核心 2010年第2期152-156,共5页 Chinese Journal of New Drugs
基金 国家重点基础研究发展计划(973计划)资助项目(2004CB518902)
关键词 神经生长因子 MPTP 帕金森病模型 鼻腔给药 nerve growth factor ( NGF ) 1-methyl-4-phenyl-1,2, 3,6-tetrahydropyridine ( MPTP ) Parkinson's disease model intranasal administration
  • 相关文献

参考文献1

二级参考文献19

  • 1[1]Zea Longa E, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989;20:84-91.
  • 2[2]Berderson JB, Pitts LH, Tsuji M, et al. Rat middle cerebral artery occlusion:evaluation of the model and development of a neurologic examination. Stroke 1986;17:472-6.
  • 3[3]De Ryck M, Van Reempts J, Borgers M, et al. Photochemical stroke model: flunarizine prevents sensorimotor deficits after neocortical infarcts in rats. Stroke 1989;20:1383-90.
  • 4[4]Feeney D, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect rate of recovery after motor cortex injury. Science 1982;217:855-7.
  • 5[5]Swanson RA, Morton MT, Tsao-Wu, et al. A semiautomated method for measuring brain infarct volume. J Cereb Blood Flow Metab 1990; 10:290-3.
  • 6[6]Aspey BS, Cohen S, Patel Y, et al. Middle cerebral artery occlusion in the rat: consistent protocol for a model of stroke. Neuropathol Appl Neurobiol 1998;24:487-97.
  • 7[7]Knusel B, Michel PP, Schwaber JS, et al. Selective and nonselective stimulation of central cholinergic and dopaminergic development in vitro by nerve growth factor, baxic fibroblast growth factor, epidermal growth factor, insulin and the insulin-like growth factors Ⅰand Ⅱ. J Neurosci 1990;10:558-70.
  • 8[8]Knusel B, Winslow JW, Rosenthal A, et al. Promotion of central cholinergic and dopaminergic neuron differentiation by brain-derived neurotrophic factor but not neurtrophin 3. Proc Natl Acad Sci USA 1991; 88: 961-5.
  • 9[9]Tsong-Hai Lee, Hiroyuki Kato, Sien-Tsong Chen, et al. Expression of nerve growth factor and trkA after transient focal cerebral ischemia in rats. Stroke 1998; 29:1687-97.
  • 10[10]Shigeno T, Mima T, Takakura K, et al. Amelioration of delayed neuronal death in the hippocampus by nerve growth factor. J Neurosci 1991;11:2914-9.

共引文献14

同被引文献45

  • 1鲍晓东.试论中医药治疗帕金森病的综合优势[J].中医杂志,2006,47(8):619-620. 被引量:26
  • 2白跃宗,夏宗勤,胡雅儿.慢性帕金森病小鼠模型的建立及其行为学稳定性研究[J].中国行为医学科学,2007,16(6):484-486. 被引量:10
  • 3Reuss B, Von Bohlen, Halbach O. Fibroblast growth factors and their receptors in the central nervous system [J]. Cell Tissue Res, 2003, 313 (2): 139-157.
  • 4Liu LH, Venkatraman SS, Yang YY, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood- brain barrier [ J ]. Biopolymers, 2008, 90 (5) : 617-623.
  • 5Wang Y, Lin HH, Lin SQ, et al. Cell-penetrating peptide TAT- mediated delivery of acidic FGF to retina and protection against ischemia-reperfusion injury in rats [J]. J Cell Mol Med, 2010, 14 (7): 1998-2005.
  • 6Huang Y, Rao YL, Feng CL, et al. High-level expression and purification of Tat-haFGF19-154[J]. Appl Mierobiol Biotechnol, 2008, 77(5): 1015-1022.
  • 7Feng J, Li FZ, Zhao Y, et al. Brain pharmacokinetics of tetram- ethylpyrazine after intranasal and intravenous administration in awake rats [J]. Int J Pharm, 2009, 375(1-2): 55-60.
  • 8Ma YP, Ma MM, Chang SM, et al. Intranasal bFGF-induced progenitor cell proliferation and neuroprotection after transient fo- cal cerebral ischemia [J]. Neurosci Lett, 2008, 437 (2): 93-97.
  • 9Ma YP, Ma MM, Ge S, et al. Intranasally delivered TGF-betal enters brain and regulates gene expressions of its receptors in rats [J]. Brain Res Bull, 2007, 74 (4): 271-277.
  • 10Wang CY, Zheng W, Wang T, et al. Huperzine A activates Wnt/ β-catenin signaling and enhances the nonamyloidogenic pathway in an Alzheimer transgenic mouse model [J]. Neuropsychophar- macology, 2011, 36 (5) : 1073-1089.

引证文献5

二级引证文献53

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部